MarketPulse

cancer prevention

2 articles
BenzingaBenzinga··Prnewswire

Lucid Diagnostics Plans Q4 2025 Earnings Call for March 26

Lucid Diagnostics ($LUCD) schedules Q4 2025 earnings call for March 26, 2026, with CEO and CFO discussing financial results and growth strategy.
LUCDPAVMearnings callcancer prevention
BenzingaBenzinga··Prnewswire

Anixa Secures Korean Patent for Breast Cancer Vaccine, Bolstering IP Portfolio

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.
ANIXintellectual propertyclinical trial